Durable survival effect observed in the largest prospective,
non-interventional study completed examining TTFields therapy use
in newly diagnosed GBM
Topline data to be presented Saturday, June 1, 2024 at the 2024
American Society of Clinical Oncology Annual Meeting in Chicago
Novocure (NASDAQ: NVCR) today released topline efficacy and
safety data from the TIGER study investigating the use of Tumor
Treating Fields (TTFields) therapy in routine clinical care in the
treatment of patients with newly diagnosed glioblastoma (GBM) in
Germany. The TIGER study enrolled 429 patients who used TTFields
therapy between August 2017 and November 2019 and is the largest
prospective, non-interventional study of the use of TTFields
therapy in routine clinical care completed to date.
Median overall survival for patients treated with TTFields
therapy was 19.6 months (95% CI, 17.9-22.4). Median
progression-free survival was 10.2 months (95% CI, 9.4-11.4).
TTFields therapy use was not associated with an increase in
systemic toxicity and was well tolerated. The outcomes observed in
the TIGER study are consistent with the survival and safety results
from Novocure’s phase 3 EF-14 clinical trial.
Patients were followed for a median duration of 56.2 months.
One-, two-, three-, and four- year survival rates were 79.2%,
42.4%, 31.5%, and 27.7%, respectively.
“As TTFields therapy use becomes more prevalent around the
globe, it is exciting to see large, prospective studies like TIGER
corroborate the survival benefits provided by using TTFields
therapy to treat newly diagnosed GBM,” said Oliver Bähr, MD,
Department of Neurology, General Hospital Aschaffenburg-Alzenau.
“The outcomes observed, particularly long-term survival rates, are
promising and make a compelling case that TTFields therapy should
be presented to all eligible GBM patients.”
“TIGER is the largest prospective, non-interventional study
analyzing TTFields therapy use in newly diagnosed GBM completed to
date,” said Nicolas Leupin, MD, Novocure’s Chief Medical Officer.
“The observations from TIGER contribute to the multitude of data
validating the use of TTFields therapy, and we are eager to
continue exploring the benefits of our therapy in both the clinical
and real-world settings.”
The TIGER data (abstract #2036) will be presented at 9:00 a.m.
CDT on Saturday, June 1, 2024 in Hall A during the Central Nervous
System Tumors session at the 2024 American Society of Clinical
Oncology Annual Meeting in Chicago.
About TIGER
TIGER (NCT03258021) is a prospective, non-interventional,
multicenter, medical device post-authorization study designed to
obtain real life data on the use of Tumor Treating Fields
(TTFields) therapy in patients with newly diagnosed glioblastoma in
routine clinical care in Germany. 710 patients with histologically
confirmed newly diagnosed glioblastoma, who had clinical indication
for TTFields therapy and were within the first 3 cycles of
maintenance chemotherapy treatment were enrolled in the study from
August 2017 to November 2019, across 81 participating centers in
Germany. 583 patients opted to use TTFields therapy, and 429
received treatment. Endpoints of the study included overall
survival, progression-free survival, safety and quality of
life.
About Tumor Treating Fields Therapy
Tumor Treating Fields (TTFields) are electric fields that exert
physical forces to kill cancer cells via a variety of mechanisms.
TTFields do not significantly affect healthy cells because they
have different properties (including division rate, morphology, and
electrical properties) than cancer cells. The multiple, distinct
mechanisms of TTFields therapy work together to selectively target
and kill cancer cells. Due to its multimechanistic actions,
TTFields therapy can be added to cancer treatment modalities in
approved indications and demonstrates enhanced effects across solid
tumor types when used with chemotherapy, radiotherapy, immune
checkpoint inhibition, or targeted therapies in preclinical models.
TTFields therapy provides clinical versatility that has the
potential to help address treatment challenges across a range of
solid tumors. To learn more about Tumor Treating Fields therapy and
its multifaceted effect on cancer cells, visit
tumortreatingfields.com.
About Novocure
Novocure is a global oncology company working to extend survival
in some of the most aggressive forms of cancer through the
development and commercialization of its innovative therapy, Tumor
Treating Fields. Novocure’s commercialized products are approved in
certain countries for the treatment of adult patients with
glioblastoma and malignant pleural mesothelioma. Novocure has
ongoing or completed clinical studies investigating Tumor Treating
Fields in brain metastases, gastric cancer, glioblastoma, liver
cancer, non-small cell lung cancer, pancreatic cancer and ovarian
cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, clinical study progress, development of
potential products, interpretation of clinical results, prospects
for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage,
collections from third-party payers and other statements regarding
matters that are not historical facts. You may identify some of
these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar
meaning. Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, environmental, regulatory and
political conditions and other more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 22, 2024, and subsequent
filings with the U.S. Securities and Exchange Commission. Given
these risks and uncertainties, any or all of these forward-looking
statements may prove to be incorrect. Therefore, you should not
rely on any such factors or forward-looking statements.
Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof.
The Private Securities Litigation Reform Act of 1995 permits this
discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522936209/en/
INVESTORS AND MEDIA: Ingrid Goldberg
investorinfo@novocure.com media@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From May 2024 to Jun 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Jun 2023 to Jun 2024